|
1
|
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.
|
Biochem Pharmacol
|
2007
|
2.05
|
|
2
|
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
|
Drug Metab Pharmacokinet
|
2005
|
1.96
|
|
3
|
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
|
Int J Clin Oncol
|
2009
|
1.82
|
|
4
|
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.
|
J Am Soc Nephrol
|
2006
|
1.80
|
|
5
|
Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin.
|
Mol Pharmacol
|
2009
|
1.53
|
|
6
|
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
|
J Pharmacol Exp Ther
|
2006
|
1.52
|
|
7
|
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain.
|
J Nutr
|
2010
|
1.47
|
|
8
|
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
|
Cancer Chemother Pharmacol
|
2012
|
1.43
|
|
9
|
Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1.
|
Am J Physiol Cell Physiol
|
2008
|
1.38
|
|
10
|
Is MIBG a substrate of P-glycoprotein?
|
Eur J Nucl Med Mol Imaging
|
2006
|
1.37
|
|
11
|
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
|
Biochem Pharmacol
|
2007
|
1.35
|
|
12
|
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).
|
Pharm Res
|
2007
|
1.32
|
|
13
|
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
|
Biochem Pharmacol
|
2005
|
1.28
|
|
14
|
Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
|
Clin Pharmacol Ther
|
2006
|
1.20
|
|
15
|
Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells.
|
J Pharmacol Exp Ther
|
2009
|
1.18
|
|
16
|
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
|
Cancer Chemother Pharmacol
|
2011
|
1.11
|
|
17
|
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
|
Pharmacogenet Genomics
|
2008
|
1.08
|
|
18
|
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
|
Biochem Pharmacol
|
2010
|
1.07
|
|
19
|
Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer.
|
Drug Metab Dispos
|
2008
|
1.06
|
|
20
|
Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1.
|
Pharm Res
|
2006
|
1.01
|
|
21
|
The transcription factor Cdx2 regulates the intestine-specific expression of human peptide transporter 1 through functional interaction with Sp1.
|
Biochem Pharmacol
|
2006
|
1.00
|
|
22
|
Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1.
|
Am J Physiol Renal Physiol
|
2006
|
0.99
|
|
23
|
Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1.
|
Drug Metab Pharmacokinet
|
2005
|
0.99
|
|
24
|
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
|
Drug Metab Pharmacokinet
|
2012
|
0.98
|
|
25
|
Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1.
|
Biochem Pharmacol
|
2008
|
0.95
|
|
26
|
Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1).
|
Am J Physiol Gastrointest Liver Physiol
|
2008
|
0.95
|
|
27
|
Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
|
Pharmacogenet Genomics
|
2006
|
0.94
|
|
28
|
Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation.
|
Am J Physiol Renal Physiol
|
2008
|
0.94
|
|
29
|
Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients.
|
Drug Metab Dispos
|
2009
|
0.92
|
|
30
|
Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis.
|
Am J Physiol Renal Physiol
|
2008
|
0.92
|
|
31
|
Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
|
Clin Pharmacol Ther
|
2005
|
0.92
|
|
32
|
Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney.
|
J Hum Genet
|
2008
|
0.91
|
|
33
|
Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1.
|
Am J Physiol Renal Physiol
|
2007
|
0.91
|
|
34
|
Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice.
|
J Pharmacol Exp Ther
|
2010
|
0.91
|
|
35
|
Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters.
|
Drug Metab Pharmacokinet
|
2010
|
0.91
|
|
36
|
Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity.
|
J Hum Genet
|
2009
|
0.90
|
|
37
|
Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
|
Biochem Pharmacol
|
2009
|
0.90
|
|
38
|
Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats.
|
Biochem Pharmacol
|
2007
|
0.90
|
|
39
|
Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients.
|
Pharmacogenet Genomics
|
2010
|
0.89
|
|
40
|
Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOCT1 and rOCT3.
|
Pharm Res
|
2006
|
0.89
|
|
41
|
Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells.
|
Am J Physiol Gastrointest Liver Physiol
|
2002
|
0.88
|
|
42
|
Induction of intestinal peptide transporter 1 expression during fasting is mediated via peroxisome proliferator-activated receptor alpha.
|
Am J Physiol Gastrointest Liver Physiol
|
2006
|
0.87
|
|
43
|
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
|
Clin Pharmacokinet
|
2013
|
0.87
|
|
44
|
The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
|
Ther Drug Monit
|
2014
|
0.87
|
|
45
|
Hepatocyte nuclear factor-4{alpha} regulates the human organic anion transporter 1 gene in the kidney.
|
Am J Physiol Renal Physiol
|
2007
|
0.86
|
|
46
|
Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: twice daily vs. once daily dosing.
|
Liver Transpl
|
2006
|
0.86
|
|
47
|
Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2.
|
Biochem Pharmacol
|
2009
|
0.85
|
|
48
|
Precise comparison of protein localization among OCT, OAT, and MATE in human kidney.
|
J Pharm Sci
|
2013
|
0.85
|
|
49
|
Characterization of the human peptide transporter PEPT1 promoter: Sp1 functions as a basal transcriptional regulator of human PEPT1.
|
Am J Physiol Gastrointest Liver Physiol
|
2005
|
0.85
|
|
50
|
Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1.
|
Biochem Pharmacol
|
2005
|
0.84
|
|
51
|
Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient.
|
Drug Metab Pharmacokinet
|
2006
|
0.84
|
|
52
|
Identification of essential histidine and cysteine residues of the H+/organic cation antiporter multidrug and toxin extrusion (MATE).
|
Mol Pharmacol
|
2007
|
0.84
|
|
53
|
Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins.
|
Pharm Res
|
2013
|
0.84
|
|
54
|
Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives.
|
J Pharmacol Exp Ther
|
2006
|
0.83
|
|
55
|
Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation.
|
J Clin Pharmacol
|
2009
|
0.82
|
|
56
|
Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract.
|
Biochem Pharmacol
|
2005
|
0.82
|
|
57
|
Thyroid hormone regulates the expression and function of P-glycoprotein in Caco-2 cells.
|
Pharm Res
|
2007
|
0.82
|
|
58
|
Repeated intravenous injection of recombinant human hepatocyte growth factor ameliorates liver cirrhosis but causes albuminuria in rats.
|
Int J Mol Med
|
2006
|
0.82
|
|
59
|
Inhibitory effect of zinc on PEPT1-mediated transport of glycylsarcosine and beta-lactam antibiotics in human intestinal cell line Caco-2.
|
Pharm Res
|
2003
|
0.82
|
|
60
|
MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients.
|
Pharm Res
|
2009
|
0.82
|
|
61
|
Impact of regulatory polymorphisms in organic anion transporter genes in the human liver.
|
Pharmacogenet Genomics
|
2009
|
0.81
|
|
62
|
[Evaluation of stability of temozolomide in solutions after opening the capsule].
|
Yakugaku Zasshi
|
2009
|
0.81
|
|
63
|
Human organic anion transporter 3 gene is regulated constitutively and inducibly via a cAMP-response element.
|
J Pharmacol Exp Ther
|
2006
|
0.80
|
|
64
|
Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1).
|
Am J Physiol Gastrointest Liver Physiol
|
2008
|
0.80
|
|
65
|
Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring.
|
Biomed Chromatogr
|
2012
|
0.80
|
|
66
|
Computational modelling of H+-coupled peptide transport via human PEPT1.
|
J Physiol
|
2005
|
0.80
|
|
67
|
Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
|
Drug Metab Pharmacokinet
|
2007
|
0.79
|
|
68
|
Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
|
Drug Metab Pharmacokinet
|
2008
|
0.79
|
|
69
|
A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data.
|
Biol Pharm Bull
|
2009
|
0.79
|
|
70
|
Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
|
Drug Metab Dispos
|
2013
|
0.78
|
|
71
|
Modulation of P-glycoprotein expression in hyperthyroid rat tissues.
|
Drug Metab Dispos
|
2005
|
0.78
|
|
72
|
Temporal decline in sirolimus elimination immediately after pancreatic islet transplantation.
|
Drug Metab Pharmacokinet
|
2006
|
0.78
|
|
73
|
Renal tubular secretion of varenicline by multidrug and toxin extrusion (MATE) transporters.
|
Drug Metab Pharmacokinet
|
2012
|
0.78
|
|
74
|
Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats.
|
Drug Metab Pharmacokinet
|
2008
|
0.77
|
|
75
|
Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein.
|
Am J Physiol Renal Physiol
|
2012
|
0.77
|
|
76
|
Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis.
|
Pharm Res
|
2005
|
0.77
|
|
77
|
Decreased activity and expression of intestinal oligopeptide transporter PEPT1 in rats with hyperthyroidism in vivo.
|
Pharm Res
|
2004
|
0.77
|
|
78
|
Effects of metabolic acidosis on expression levels of renal drug transporters.
|
Pharm Res
|
2010
|
0.76
|
|
79
|
Characterization of the Basal promoter element of human organic cation transporter 2 gene.
|
J Pharmacol Exp Ther
|
2007
|
0.76
|
|
80
|
Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.
|
Biochem Pharmacol
|
2007
|
0.76
|
|
81
|
Prediction of glycylsarcosine transport in Caco-2 cell lines expressing PEPT1 at different levels.
|
Pflugers Arch
|
2005
|
0.76
|
|
82
|
Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus.
|
Drug Metab Pharmacokinet
|
2009
|
0.75
|
|
83
|
Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile.
|
Drug Metab Pharmacokinet
|
2008
|
0.75
|
|
84
|
Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.
|
Biopharm Drug Dispos
|
2009
|
0.75
|
|
85
|
Cl- -dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3.
|
Am J Physiol Renal Physiol
|
2007
|
0.75
|
|
86
|
Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats.
|
Drug Metab Pharmacokinet
|
2008
|
0.75
|
|
87
|
Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic study.
|
Hepatol Res
|
2013
|
0.75
|
|
88
|
A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection.
|
Drug Metab Pharmacokinet
|
2010
|
0.75
|
|
89
|
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
|
Pharmacogenet Genomics
|
2017
|
0.75
|
|
90
|
Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
|
Biol Pharm Bull
|
2006
|
0.75
|